Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 1028 Show results per page	View Search Criteria \| Help With Results

Last Modified: 6/1/2001 First Published: 9/1/1998


1.		Phase IV Study of Allogeneic Bone Marrow Transplantation Depleted of T-Cells by CD34 Selection in Patients Undergoing Transplantation with a Matched or Mismatched Antigen Donor

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Closed				50 and under				Other				MSGCC-9739 NCI-V98-1433, NCT00003398

Last Modified: 7/18/2007 First Published: 2/1/2002


2.		Phase IV Randomized Study of Filgrastim (G-CSF) or Pegfilgrastim as Secondary Prophylaxis Versus Conservative Management of Chemotherapy-Induced Neutropenia for Maintenance of Chemotherapy in Women With Early Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Supportive care				Closed				18 and over				Other				ACCOG-SCTN-BR0101 SCTN-BR0101, EU-20143, NCT00030758

Last Modified: 12/1/1998


3.		Phase II/III Randomized Study of Monoclonal Antibody HuM195 As Maintenance Therapy in Elderly Patients with Acute Myeloid Leukemia in Complete Remission Following Chemotherapy (Summary Last Modified 12/98)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				60 and over				Pharmaceutical / Industry				PDL-3-251 MSKCC-93131, NCI-V94-0469

Last Modified: 11/1/1997


4.		Phase II/III Pilot Treatment of Pediatric Non-B, Non-T ALL in First Marrow Relapse (SIMAL #8): Intensive Re-Induction and Reconsolidation Chemotherapy with Subsequent Myeloablative Chemoradiotherapy and Rescue with Either Allogeneic or In Vitro-Purged Autologous Marrow (Summary Last Modified 11/97)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				under 21 at relapse				NCI				POG-9410 POG-SIMAL-8

Last Modified: 7/11/2007 First Published: 4/1/1998


5.		Phase II/III Randomized Study of Conventional vs T cell Depleted Unrelated Donor Bone Marrow Transplantation for Leukemia, Myelodysplasia, and Lymphoblastic Lymphoma (Summary Last Modified 02/2001)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				55 and under				NCI				MCV-CCHR-9504-2X DUMC-75951, NCI-G98-1388, NCT00003187

Last Modified: 7/11/2007 First Published: 2/1/2000


6.		Phase II/III Randomized Study of Processed Versus Unprocessed Unrelated Bone Marrow Transplantation in Patients With Acute or Chronic Leukemia or Myelodysplastic Syndromes

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Supportive care, Treatment				Completed				12 to 50				Other				CHIMERIC-HM01 WSU-10-02-99-M01-FB, NCT00004255

Last Modified: 10/24/2008


7.		Phase II/III Randomized Comparison of Consolidation with Intensive Chemotherapy Using CDDP/VP-16/DOX/IFF vs Myeloablative Chemoradiotherapy and Autologous Marrow Rescue and of Continuation Therapy with Isotretinoin vs No Further Therapy in High-Risk Neuroblastoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				0 to 18				NCI				CCG-3891

Last Modified: 5/10/2007


8.		Phase II/III Randomized Trial of DOX vs TAX vs DOX/TAX/G-CSF in Patients with Metastatic Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				any age				NCI				E-1193 NCCTG-923252, SWOG-9332, E-10292, E1193

Last Modified: 12/6/2007 First Published: 9/24/2003


9.		Phase II/III Randomized Study of Immunotherapy Comprising Cyclosporine, Interferon Gamma, and Interleukin-2 After High-Dose Myeloablative Chemotherapy With Autologous Stem Cell Transplantation in Patients With Refractory or Relapsed Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				Under 30				NCI				COG-AHOD0121 NCT00070187, AHOD0121


10.		Rituximab+Standard CHOP vs Rituximab+bi-Weekly CHOP for Untreated Stage III/IV Low-Grade B-Cell Lymphoma (JCOG0203)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				20 to 69				Other				JCOG0203 C000000033, NCT00147121

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute